tesamorelin ipamorelin blend vial: Frequently asked questions

Discard the vial immediately. Cloudiness or particulate formation indicates peptide aggregation, bacterial contamination, or chemical degradation—none of which are reversible. Aggregated peptides lose biological activity and can trigger immune responses if administered. This failure mode is most common when vials are stored above 8°C, subjected to freeze-thaw cycles, or punctured with non-sterile needles. Review your storage conditions: ensure the refrigerator maintains 2–8°C consistently (verify with a thermometer, not the appliance display) and that you're using fresh alcohol swabs for every needle puncture. If the problem recurs across multiple vials, the issue is environmental—not the peptide itself.

Recalculate your dose immediately using the actual concentration. If you added 2mL instead of 3mL to a 15mg vial, your concentration is 7.5mg/mL instead of 5mg/mL—meaning each 0.1mL draw now contains 750mcg instead of 500mcg. To correct for 500mcg dosing, draw 0.067mL per injection, but recognize this introduces measurement error with standard insulin syringes. If the error makes dosing impractical, discard the vial and reconstitute a fresh one—peptide waste is cheaper than protocol invalidation from inconsistent dosing. The mistake is most common when researchers prep multiple vials simultaneously or switch between vial sizes mid-protocol without adjusting their water volume.

Order two 20mg vials (10mg/10mg each) and reconstitute each with 4mL bacteriostatic water for 5mg/mL concentration. Each vial yields 40 doses at 500mcg per injection—two vials cover 80 doses, sufficient for 12 weeks at five doses per week with a 20-dose buffer. Use one vial completely before opening the second to minimize the number of vials in active refrigeration simultaneously. Track puncture dates and discard any vial that has been reconstituted for more than 28 days, even if peptide remains. Extending beyond 28 days risks bacterial contamination that no visual inspection can detect.

Use a smaller tesamorelin + ipamorelin blend vial size or increase reconstitution volume to lower concentration. For 100mcg per peptide (200mcg total dose), a 10mg vial reconstituted with 5mL yields 2mg/mL—each 0.1mL contains exactly 200mcg. Alternatively, use a 5mg/5mg vial with 2.5mL reconstitution for the same 2mg/mL concentration with less total peptide waste. Lower concentrations require larger injection volumes, but for subcutaneous administration, volumes up to 0.5mL per site are well-tolerated in most research models. Never attempt to measure doses below 0.05mL with standard syringes—measurement error exceeds 50% at that volume.

It depends on ambient temperature. At 20–22°C for six hours, the vial retains approximately 88–92% potency and remains microbiologically safe due to benzyl alcohol preservation. At 25–28°C, potency drops to 80–85%, and bacterial growth risk increases meaningfully. The conservative standard: if room temperature exceeded 25°C or the duration exceeded eight hours, discard the vial. If conditions were moderate (20–23°C, under six hours), you can continue using it with the understanding that all subsequent doses operate at reduced potency. Do not extend the protocol timeline to compensate, as bacterial contamination risk increases faster than potency declines.

Buy the single 10mg vial. It covers 20 doses with a 10-dose buffer, fits entirely within the 28-day stability window, and eliminates the mid-protocol reconstitution step that introduces contamination risk. Two 5mg vials require two separate reconstitution events, doubling needle punctures and bacterial exposure points. The unused 10 doses from the 10mg vial represent material cost, but the reduced contamination risk and simplified protocol logistics justify that expense in research settings where replication reliability matters more than marginal material savings.

Most likely, yes. But the error isn't in your dosing volume. It's in your reconstitution volume or needle dead space accumulation. If you reconstituted with less than 2mL bacteriostatic water, each 0.067mL draw contains proportionally more peptide, causing you to deplete the vial faster. Additionally, standard insulin syringes retain 0.02–0.03mL dead space per injection. Over 25 doses, this accumulates to 0.5–0.75mL of unusable solution trapped in discarded syringes. To prevent this, reconstitute with 2.1–2.2mL bacteriostatic water to account for dead space loss, or switch to low-dead-space syringes that retain <0.01mL per dose.

Discard the vial immediately. Tesamorelin and Ipamorelin undergo irreversible aggregation when held at room temperature (20–25°C) for more than two hours. Overnight exposure (8–12 hours) guarantees complete loss of structural integrity. The peptide may still look clear and sterile, but the amino acid chains have clumped into inactive aggregates that no longer bind to ghrelin or GHRH receptors. Using degraded peptide introduces uncontrolled variability into your research and produces unreliable results. There is no method to confirm potency at home, and attempting to 'rescue' the vial by refrigerating it afterward does not reverse the damage.

Use a portable medical cooler with temperature monitoring capability. The vial must remain between 2–8°C during the entire transport window. Standard insulated lunch boxes and ice packs are insufficient because they do not maintain precise temperature control and can cause freezing if the ice pack contacts the vial directly. Purpose-built insulin travel cases like the FRIO wallet use evaporative cooling and maintain 2–8°C for 36–48 hours without electricity or ice. If transport time exceeds 48 hours or external temperature exceeds 30°C, cold chain integrity cannot be guaranteed with passive cooling alone. Consider shipping the unreconstituted lyophilised vial instead and reconstituting it upon arrival.

Discard it. The 28-day stability window is a conservative clinical standard based on the period during which peptides maintain at least 90% of their original potency under ideal conditions. After 28 days, hydrolysis and oxidation have measurably reduced peptide concentration and altered the amino acid sequence in ways that compromise receptor binding. Continuing to use solution beyond this window means you cannot accurately calculate dose or predict biological activity. Your protocol loses experimental validity. If you consistently have significant volume remaining at the 28-day mark, reduce your reconstitution volume or purchase smaller vials matched to your actual usage rate.

This is acceptable if performed under strict sterile technique immediately after reconstitution. Use sterile transfer needles and pre-sterilized glass vials with rubber stoppers. Never reuse empty vials from previous batches. Draw half the reconstituted solution into a sterile syringe, inject it into the second sterile vial, and seal immediately. Label both vials with the reconstitution date and peptide concentration. Both vials are now subject to the same 28-day stability window. Splitting vials reduces the number of needle punctures per stopper, which extends seal integrity and reduces contamination risk for protocols requiring 20+ injections.